Subscribe to Blog via Email
An Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) – now that sounds exiting.
It doesn’t seem that long since we got the new improved injection delivery system for the current model of Lanreotide. I had to look at my blog articles for the announcement of that and was surprised it was way back in 2019. It may be a shorter time period for many though, UK was near the front of that rollout. I personally found the new injection a better experience and I know the nurses were happier too. However, I also know there was some disappointment that the injection gauge and length were the same and therefore there was little change for many in terms of the ‘experience’. Speaking from a personal perspective, there was not sufficient change for me to consider moving to self-inject. I know (at least in UK) Ipsen is keen to move as many people as possible over to self-inject, most likely to reduce costs on the Ipsen Homezone programme – I get that. I think the next generation delivery system could well be a game-changer in that department, read more below.
Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product. Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document. Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET
Ipsen Press Release: March 16, 2022 2:30 AM
- New electronic autoinjector is designed to improve patient experience for people living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegaly
- Performance and safety studies ongoing, with first launches for the new device expected in 2024
- A fourth-generation Somatuline® Autogel® / Somatuline® Depot device building on Ipsen’s 20 years’ heritage to date
Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will invest in a new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide), to deliver further innovation in the class with the aim of improving administration and the injection experience for patients. The new device will be made in collaboration with Phillips-Medisize, global leaders in drug-delivery design, development and manufacturing solutions, and will be accompanied by enhanced investment in Ipsen’s Signes manufacturing site in France.
Despite advances in technology, real-world evidence suggests people living with gastroenteropancreatic neuroendocrine tumors or acromegaly often still experience pain and discomfort when receiving injections. The enhanced delivery system will improve the patient experience through administration of Somatuline Autogel / Somatuline Depot via its motorized device comprised of a re-usable electronic injector and a disposable cartridge with significantly thinner injection needle allowing for a controlled and sustained injection. The new device aims to further improve the injection experience, especially for caregivers and eligible patients who may choose independent administration of Somatuline Autogel, for example at home.
Ipsen’s extensive experience with Somatuline Autogel / Somatuline Depot has offered deep insights into the challenges of living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegaly. Advances in administration are important as they have the potential to help ease the physical challenges of treatment for the patient, caregiver and their healthcare team, especially for patients who are on long-term treatment regimens.
Studies evaluating the performance and the safety of the new device are ongoing. A study assessing injection-site pain and device safety is expected to start in the first half of 2023 and will evaluate patient-reported outcomes and satisfaction. Details of this study will be available once the selected centers have been finalized in H2 2022 and I will bring you this as soon as it is published. The new device is anticipated to reach the first patients in 2024
One of my alerts stated that Ipsen was intending to use an autoinjector device provided by a company called Phillips Medisize. I can see from other searches on Phillips Medisize that they announced this product in 2021 as a “low-waste digital drug delivery device”. I’m confidentially going to suggest the improved Lanreotide is going to be based on the “The Aria smart autoinjector” (which includes a + model). I’m not saying the improved Lanreotide will look exactly like this but if my prediction is accurate, I don’t see how it can be much different. If you keep reading, you will see why. I quoted above from an Ipsen newsletter that the device has two components: firstly, the reusable autoinjector part and secondly the disposable part containing the drug and needle. I also said it was the electronic injector was re-useable and the drug part was a single use cassette type affair than can be discarded as medical waste (perhaps in sharps bins). Perhaps the cassette drug element might look different from the one in the picture below. The marketing for this product alludes to an app being available but that would not necessarily be required for Lanreotide (tbc).
Click here for more info on the Phillips Medisize Aria smart autoinjector.
Click below to watch a short video about Phillips Medisize Aria smart autoinjector. Please bear in mind it might be a different protocol with Lanreotide.
From above we know there will be an electronic injector of some sort and I suspect that will be operated by a button push. It has green credentials in that the electronic injector section is re-usable (the example above is said to have a battery life of 3 years) but there is a disposable cartridge that I suspect will contain the needle and the drug. I also know it will be a “significantly” thinner needle, welcome news for many. Ipsen predicts the new device will further improve the injection experience and perhaps the combination of these changes will make self-injection a much simpler and less anxious choice. Clinical trials are likely to start in 2023 and I will of course bring you those details as soon as they are published. This is most likely to be an international trial given Ipsen’s reach.
I’ll keep my ear to the ground for future updates.
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Sign up for my newsletters – Click Here
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
What is Carcinoid Syndrome?Carcinoid syndrome (CS) is the most frequent hormonal complication accompanying neuroendocrine neoplasms (NENs) and is defined by chronic diarrhoea and/or flushing in the presence
I was delighted to see this clinical trial which looks at the efficacy of PRRT (Lu177) vs the efficacy of Everolimus (Afinitor). The latter is
November is always busier as I help spread awareness for 10th Nov (remembering that every day is 10th Nov on my site!). I also managed
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in anatomical terms. Gastric neuroendocrine
A cup of tea
I would also mention those who contributed to my “Tea Fund” which resides on PayPal. You don’t need a PayPal account as you can select a card but don’t forget to select the number of units first (i.e. 1 = £4, 2 = £8, 3 = £12, and so on), plus further on, tick a button to NOT create a PayPal account if you don’t need one. Clearly, if you have a PayPal account, the process is much simpler
Through your generosity, I am able to keep my sites running and provide various services for you. I have some ideas for 2023 but they are not detailed enough to make announcements yet.
This screenshot is from every single post on my website and depending on which machine you are using, it will either be top right of the post or at the bottom (my posts are often long, so scroll down!)